 |
||||||
 |
 |
 |
|
|
|
|
 |
|||||
 |
|
||||
 |
|||||
 |
|
 |
|||
 |
|||||
|
|||||
Investment Highlights
- Leading brand name in blood processing
- Global market share leader
- Reputation for innovation
- Cash generating business model
- Sustained operating leverage
Financial Highlights
| $ in millions, except share date | 2003 | 2004 | 2005 | 2006 | 2007 | |
|---|---|---|---|---|---|---|
| Net revenues | $337 | $364 | $384 | $420 | $450 | |
| Gross profit | 155 | 174 | 198 | 221 | 228 | |
| R&D expenses | 20 | 17 | 20 | 27 | 24 | |
| Total operating expenses | 117 | 126 | 138 | 148 | 147 | |
| Operating income | 37 | 47 | 60 | 73 | 80 | |
| Net income | $28 | $29 | $40 | $52 | $60 | |
| Net income per share (diluted) | $1.13 | $1.19 | $1.52 | $1.90 | $2.17 | |
| Cash flow from operations | $47 | $77 | $71 | $86 | $86 | |
| Cash and short-term investments | 50 | 118 | 186 | 251 | 229 | |
| Debt | 71 | 58 | 46 | 39 | 29 | |
*Excludes the benefit of arbitration awards received in 2005 and 2006 as well as in-process R&D, restructuring, and other charges in 2006 and 2007. Results are reconciled to GAAP on the non-GAAP financials section of this website as well as in the annual earnings press releases.
Strategy Highlights
- Leverage core business for greater profitability
- Expand business by leveraging core competencies
View highlights of Haemonetics' performance versus its strategy
Sign up for e-mail notifications
*Excludes the benefit of a $30.8 million arbitration award; results are
reconciled on the Non-GAAP financials section of this website.
|
Products and Services · News · Events · Careers · Investors · Media · Companies · Contact Us · Privacy Statement · Terms of Use · Site Map · Home © 2008, Haemonetics Corp., 400 Wood Rd., Braintree, MA, 02184, USA Tel: (800) 225-5242 || Website Design by Garfield Group |
